Skip to content

Released Aug 13, 2019, after the close

10-Q filed Aug 14, 2019, 45 days after period end · 0001564590-19-031883

Q2 2019 · 10-Q
Revenue$10.53M+84.5% vs Q2 2018+22.0% vs Q1 2019
Net Income-$13.79MN/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.60N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$13,685,000N/M
Operating Cash Flowderived-$15,601,000N/M
Free Cash Flowderived-$16,090,000N/M
Margins · derived
Operating margin-130.0%+81.9 pt vs Q2 2018
Net margin-131.0%+71.3 pt vs Q2 2018

What the release said

The release

Same quarter

MetricQ2 2019Q2 2018Q2 2017
Revenue$10.53M$5.70M$15.36M
Net Income-$13.79M-$11.54M-$1.81M
EPS Diluted-$0.60-$24.17-$4.07

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR